Cargando…

DDEL-06. DRUG INTERACTION BETWEEN EVEROLIMUS AND CANNABIDIOL IN PEDIATRIC PATIENTS WITH SUBEPENDYMAL GIANT CELL ASTROCYTOMAS: A SINGLE INSTITUTION EXPERIENCE

Tuberous sclerosis complex (TSC) is an autosomal recessive genetic disorder associated with clinical manifestations including subependymal giant cell astrocytomas (SEGA) and seizures. The combination of everolimus and Epidiolex, a purified form of cannabidiol, has become an increasingly common treat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sabus, Ashley, Winzent, Shelby, Hemenway, Molly, Levy, Jean Mulcahy, Foreman, Nicholas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Drug Delivery/Pharmacokinetics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7715614/ http://dx.doi.org/10.1093/neuonc/noaa222.041

Ejemplares similares

DDEL-06. Drug Delivery to the Pons Using Short-Pulse Focused Ultrasound and Microbubble Exposure for the Treatment of Diffuse Midline Glioma
por: Chattenton, Dani, et al.
Publicado: (2022)

DDEL-17. TRIPLE INTRAVENTRICULAR CHEMOTHERAPY FOR TREATMENT OF RELAPSED CHOROID PLEXUS CARCINOMA
por: Lau, Grace, et al.
Publicado: (2020)

DDEL-12. NANOPARTICLE DELIVERY OF DOXORUBICIN FOR THE TREATMENT OF DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG)
por: Ung, Caitlin, et al.
Publicado: (2020)

DDEL-04. ENGINEERED NANOCARRIERS TO ENHANCE DRUG DELIVERY ACROSS THE BLOOD-BRAIN BARRIER
por: Straehla, Joelle P, et al.
Publicado: (2020)

DDEL-02. Intra-arterial Delivery for Novel Combinatorial Chemotherapies in Choroid Plexus Carcinoma
por: Martin, Brice, et al.
Publicado: (2022)

DDEL-01. ENHANCING DRUG DELIVERY WITH MRgFUS FOR DIFFUSE INTRINSIC PONTINE GLIOMA MODEL
por: Ishida, Joji, et al.
Publicado: (2020)

DDEL-15. NANOTHERAPEUTIC TARGETING OF TUMOR ENDOTHELIUM FOR ENHANCING DRUG DELIVERY PAST THE BLOOD-BRAIN BARRIER
por: Kiguchi, Hiro, et al.
Publicado: (2020)

DDEL-11. CONVECTION-ENHANCED DELIVERY OF EZH2 INHIBITOR FOR THE TREATMENT OF DIFFUSE INTRINSIC PONTINE GLIOMA
por: Sasaki, Takahiro, et al.
Publicado: (2020)

DDEL-14. SAFETY OF INTERVENTRICULAR METHOTREXATE ADMINISTRATION FOLLOWING RADIATION IN PEDIATRIC PATIENTS WITH MALIGNANT BRAIN TUMORS
por: Rosales, Kristofer, et al.
Publicado: (2020)

DDEL-08. CONVECTION-ENHANCED DELIVERY OF NIMUSTINE HYDROCHLORIDE (ACNU) AGAINST PEDIATRIC DIFFUSE INTRINSIC PONTINE GLIOMAS
por: Saito, Ryuta, et al.
Publicado: (2020)

DDEL-03. The use of programmable valves as a vehicle for intrathecal chemotherapy delivery in infants with CNS tumors and hydrocephalus.
por: Dvir, Rina, et al.
Publicado: (2022)

DDEL-10. A NANOPARTICLE PLATFORM FOR INTRATHECAL DELIVERY OF THE HISTONE DEACETYLASE INHIBITOR (HDACi) PANOBINOSTAT IN METASTATIC OR RECURRENT MEDULLOBLASTOMA
por: Chaudhuri, Sauradip, et al.
Publicado: (2020)

DDEL-05. Intraventricular therapy with topotecan is feasible and safe: Experience in 50 pediatric patients with various malignant brain tumors
por: Peyrl, Andreas, et al.
Publicado: (2022)

DDEL-03. LONG-TERM INTRAVENTRICULAR THERAPY ALTERNATING ETOPOSIDE AND LIPOSOMAL CYTARABINE: EXPERIENCE IN 75 CHILDREN AND ADOLESCENTS WITH MALIGNANT BRAIN TUMORS
por: Stepien, Natalia, et al.
Publicado: (2020)

DDEL-09. HIGH DOSE MTX110 (SOLUBLE PANOBINOSTAT) SAFELY ADMINISTERED INTO THE FOURTH VENTRICLE IN A NON-HUMAN PRIMATE MODEL
por: Sirianni, Rachael W, et al.
Publicado: (2020)

DDEL-05. BLOOD-BRAIN BARRIER DISRUPTION AND ENHANCED RADIOSENSITIZERS EXTRAVASATION UPON FOCUSED ULTRASOUND FOR TREATMENT OF DIFFUSE INTRINSIC PONTINE GLIOMA
por: Hart, Elvin ‘t, et al.
Publicado: (2020)

DDEL-13. FOCUSED ULTRASOUND MEDIATED BLOOD BRAIN BARRIER DISRUPTION IN A MURINE MODEL OF PONTINE GLIOMA: A SAFETY AND FEASIBILITY STUDY
por: Englander, Zachary, et al.
Publicado: (2020)

DDEL-16. UNDERSTANDING OPTIMAL CONVECTION-ENHANCED DELIVERY PHYSICO-CHEMICAL INFUSION PARAMETERS: THE ROLE OF BBB EFFLUX PUMPS IN DRUG DISTRIBUTION AND CLEARANCE
por: Power, Erica, et al.
Publicado: (2020)

DDEL-07. A PHASE I STUDY EXAMINING THE FEASIBILITY OF INTERMITTENT CONVECTION-ENHANCED DELIVERY (CED) OF MTX110 FOR THE TREATMENT OF CHILDREN WITH NEWLY DIAGNOSED DIFFUSE MIDLINE GLIOMAS
por: Zacharoulis, Stergios, et al.
Publicado: (2020)

DDEL-07. A Phase I study examining the feasibility of intermittent convection-enhanced delivery (CED) of MTX110 for the treatment of children with newly diagnosed diffuse midline gliomas (DMGs)
por: Zacharoulis, Stergios, et al.
Publicado: (2022)

DDEL-04. Pharmacokinetic/Pharmacodynamic analysis of the DNA methyltransferase inhibitor 5-azacytidine shows adequate brain tissue penetration with intravenous administration in a DIPG mouse patient-derived xenograft model.
por: Groves, Andrew, et al.
Publicado: (2022)

DDEL-02. DECREASED TOXICITY OF CONVENTIONAL DOSE CHEMOTHERAPY UTILIZING BODY WEIGHT INSTEAD OF BODY SURFACE AREA FOR DOSING IN YOUNG CHILDREN <6 YEARS OLD ENROLLED ON THE “HEAD START” 4 CLINICAL TRIAL
por: Dhall, Girish, et al.
Publicado: (2020)

MODL-01. SAFETY IN CONCOMITANT USE OF MEK AND BRAF INHIBITORS WITH BEVACIZUMAB
por: Winzent, Shelby, et al.
Publicado: (2020)

Everolimus for subependymal giant cell astrocytoma: 5‐year final analysis
por: Franz, David N., et al.
Publicado: (2015)

Neoadjuvant Therapy with Everolimus for Subependymal Giant Cell Astrocytoma: A Case Report
por: KARITA, Hiroki, et al.
Publicado: (2023)

The Effect of Everolimus on Subependymal Giant Cell Astrocytoma (SEGA) in Children with Tuberous Sclerosis Complex
por: BAKHTIARY, Hassan, et al.
Publicado: (2021)

Subependymal giant cell astrocytoma: Cytological findings
por: Azarpira, Negar, et al.
Publicado: (2012)

Infantile atypical subependymal giant cell astrocytoma
por: Almubarak, Abdulaziz O., et al.
Publicado: (2020)

Everolimus in the treatment of subependymal giant cell astrocytomas, angiomyolipomas, and pulmonary and skin lesions associated with tuberous sclerosis complex
por: Franz, David Neal
Publicado: (2013)

EFFECTS: an expanded access program of everolimus for patients with subependymal giant cell astrocytoma associated with tuberous sclerosis complex
por: Fogarasi, Andras, et al.
Publicado: (2016)

The effect of everolimus on renal angiomyolipoma in pediatric patients with tuberous sclerosis being treated for subependymal giant cell astrocytoma
por: Bissler, John J., et al.
Publicado: (2017)

Adverse Events of Everolimus in Patients with Tuberous Sclerosis Complex Treated for Renal Angiomyolipoma/Subependymal Giant Cell Astrocytoma
por: Gau, Shuo-Yan, et al.
Publicado: (2023)

Maintenance Therapy With Everolimus for Subependymal Giant Cell Astrocytoma in Patients With Tuberous Sclerosis – Final Results From the EMINENTS Study
por: Bobeff, Katarzyna, et al.
Publicado: (2021)

Intraoperative Squash Cytologic Features of Subependymal Giant Cell Astrocytoma
por: Nasit, Jitendra, et al.
Publicado: (2016)

The Clinical Characteristics of Subependymal Giant Cell Astrocytoma: Five Cases
por: Jung, Tae-Young, et al.
Publicado: (2015)

From the bench to the bedside: Everolimus for subependymal giant cell astrocytomas in Tuberous sclerosis complex, optic nerve regeneration, targeted cytotoxins for gliomas
por: Hauptman, Jason S.
Publicado: (2011)

Imaging Manifestations of a Subependymal Giant Cell Astrocytoma in Tuberous Sclerosis
por: Stein, Joseph R., et al.
Publicado: (2016)

Congenital subependymal giant cell astrocytomas in patients with tuberous sclerosis complex
por: Kotulska, Katarzyna, et al.
Publicado: (2014)

Clinical Characteristics of Subependymal Giant Cell Astrocytoma in Tuberous Sclerosis Complex
por: Jansen, Anna C., et al.
Publicado: (2019)

The coding and non-coding transcriptional landscape of subependymal giant cell astrocytomas
por: Bongaarts, Anika, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_s810fmqdie6aig1rvp3qjl02d9